ORUDIS KT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Orudis Kt, and when can generic versions of Orudis Kt launch?
Orudis Kt is a drug marketed by Wyeth Cons and is included in one NDA.
The generic ingredient in ORUDIS KT is ketoprofen. There are twenty-seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ketoprofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Orudis Kt
A generic version of ORUDIS KT was approved as ketoprofen by TEVA on December 22nd, 1992.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ORUDIS KT?
- What are the global sales for ORUDIS KT?
- What is Average Wholesale Price for ORUDIS KT?
Summary for ORUDIS KT
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 166 |
Clinical Trials: | 2 |
Patent Applications: | 55 |
DailyMed Link: | ORUDIS KT at DailyMed |
Recent Clinical Trials for ORUDIS KT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Rochester | Phase 2/Phase 3 |
Mae Stone Goode Foundation | Phase 2/Phase 3 |
Sanford Research | Early Phase 1 |
US Patents and Regulatory Information for ORUDIS KT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wyeth Cons | ORUDIS KT | ketoprofen | TABLET;ORAL | 020429-001 | Oct 6, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |